🧾 What This Document Is

This is a 6-K form, which is a current report filed with the SEC by foreign companies (like Danish Genmab) to share important events with U.S. investors. This specific filing is a "Major Shareholder Announcement." It's like a mandatory public notification saying, "Hey, a big investor just crossed an important ownership threshold."

🏢 What The Company Does

👉 In simple terms, Genmab is a cutting-edge biotech company that invents and builds advanced antibody medicines to fight cancer and other serious diseases. They are like master architects for the immune system, designing specific molecules (antibodies) to target illnesses. Their science has already led to eight approved drugs, and they have more promising treatments in late-stage testing. The company is based in Copenhagen, Denmark, but operates globally.

👥 The Big Shareholder Update

The core news is that Orbis Investment Management Limited now controls 4.99% of Genmab's total shares and voting rights. 👉 This is a critical figure because in many jurisdictions, crossing the 5% ownership mark triggers a public disclosure requirement. Orbis is right at the edge, just under 5%, making this a notable signal to the market about who is buying a significant stake in the company.

• Investor: Orbis Investment Management Limited
• Stake: 3,205,763 shares
• Percentage: 4.99% of share capital & voting rights
• Date of Change: March 27, 2026

🔮 What This Signals

While one shareholder moving to 4.99% doesn't change how the company is run, it's a piece of market intelligence. 👉 It tells us that a sizable institutional investor believes in Genmab's long-term value enough to accumulate a major position. For other investors, it can be a data point to gauge market sentiment and who is "betting" on the company's future in cancer therapy.

🌍 Industry Context

The biotech sector is driven by scientific breakthroughs and clinical trial results. In this world, Genmab is a respected, established player with a proven track record of getting drugs approved. 👉 Shareholder movements like this happen against a backdrop of intense focus on Genmab's pipeline—will their next drug be a success? Big investors positioning themselves often reflect confidence in that pipeline's potential.

⚖️ Big Picture

👍 Strengths: A validated platform with multiple approved drugs, a strong clinical pipeline, and now attracting significant investment from major funds like Orbis. ⚠️ Risks: Biotech is inherently risky. Future success depends on expensive clinical trials working, regulatory approvals, and competing with other companies. Drug development can fail.

🧠 The Analogy

This announcement is like a well-known food critic quietly buying a 4.99% stake in a popular restaurant. It doesn't change the menu or the chefs today, but it’s a strong public signal that someone with deep expertise thinks the restaurant’s future looks very tasty.

📇 Key Contacts & People

• Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
  • T: +1 609 524 0065
  • E: [email protected]
• Andrew Carlsen, Vice President, Head of Investor Relations
  • T: +45 3377 9558
  • E: [email protected]

🧩 Final Takeaway

A major investment firm, Orbis, has built a nearly 5% stake in Genmab, publicly signaling its confidence in the biotech company's mission to create groundbreaking cancer medicines. It's a noteworthy vote of confidence from a sophisticated investor.